479580-97-7

Upstream product

• 592508-69-5 4-(4-isobutyl-phenoxy)-benzaldehyde 
• 4167-74-2 4-isobutylphenol 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 592508-75-3 C₁₉H₂₂O₂ 
• 656235-21-1 2-imino-5-(4-{3-[4-(4-isobutyl-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-thiazolidin-4-one 
• 592508-51-5 hydroxy-(4-{3-[4-(4-isobutyl-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-acetic acid methyl ester 
• 606966-65-8 hydroxy-(3-{3-[4-(4-isobutyl-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-acetic acid methyl ester 
• 592508-78-6 4-(4-isobutyl-phenoxy)-2-propyl-phenol 

Relevant academic research and scientific papers

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.

5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents

A novel series of 5-aryl thiazolidine-2,4-diones based dual PPARα/γ agonists was identified. A number of highly potent and orally bioavailable analogues were synthesized. Efficacy study results of some of these analogues in the db/db mice model of type 2 diabetes showed them superior to rosiglitazone in correcting hyperglycemia and hypertriglyceridemia.